ERS statement on harmonised standards for lung cancer registration and lung cancer services in Europe.

The European Respiratory Society (ERS) task force for harmonised standards for lung cancer registration and lung cancer services in Europe recognised the need to create a single dataset for use in pan-European data collection and a manual of standards for European lung cancer services.The multidisciplinary task force considered evidence from two different sources, reviewing existing national and international datasets alongside the results of a survey of clinical data collection on lung cancer in 35 European countries. A similar process was followed for the manual of lung cancer services, with the task force using existing guidelines and national or international recommendations for lung cancer services to develop a manual of standards for services in Europe.The task force developed essential and minimum datasets for lung cancer registration to enable all countries to collect the same essential data and some to collect data with greater detail. The task force also developed a manual specifying standards for lung cancer services in Europe.Despite the wide variation in the sociopolitical landscape across Europe, the ERS is determined to encourage the delivery of high-quality lung cancer care. Both the manual of lung cancer services and the minimum dataset for lung cancer registration will support this aspiration.
Competing Interests: Conflict of interest: A.L. Rich has nothing to disclose. Conflict of interest: D.R. Baldwin reports personal fees for lecturing from AstraZeneca, outside the submitted work. Conflict of interest: P. Beckett has nothing to disclose. Conflict of interest: T. Berghmans has nothing to disclose. Conflict of interest: J. Boyd is an employee of the European Lung Foundation. Conflict of interest: C. Faivre-Finn reports research funding and business travel support from Merck, AstraZeneca and Pfizer, outside the submitted work. Conflict of interest: F. Galateau Salle has nothing to disclose. Conflict of interest: F. Gamarra has nothing to disclose. Conflict of interest: B. Grigoriu has nothing to disclose. Conflict of interest: N-C.G. Hansen has nothing to disclose. Conflict of interest: G. Hardavella has nothing to disclose. Conflict of interest: E. Jakobsen has nothing to disclose. Conflict of interest: D. Jovanovic has nothing to disclose. Conflict of interest: A. Konsoulova has nothing to disclose. Conflict of interest: G. Massard has nothing to disclose. Conflict of interest: J. McPhelim reports personal fees from Roche, MSD, Pfizer, Lilly Oncology and Abbvie, outside the submitted work. Conflict of interest: A-P. Meert has nothing to disclose. Conflict of interest: R. Milroy has nothing to disclose. Conflict of interest: L. Mutti has nothing to disclose. Conflict of interest: M. Paesmans has nothing to disclose. Conflict of interest: M.D. Peake has nothing to disclose. Conflict of interest: P.M. Putora has nothing to disclose. Conflict of interest: D.K.M. de Ruysscher has nothing to disclose. Conflict of interest: J-P. Sculier has nothing to disclose. Conflict of interest: A. Schepereel has nothing to disclose. Conflict of interest: D.R. Subotic has nothing to disclose. Conflict of interest: P. Van Schil has nothing to disclose. Conflict of interest: T.G. Blum has nothing to disclose.
(Copyright ©ERS 2018.)